PanCareLIFE researchers in UNIBE have published ‘Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers’ in Quality of Life Research (https://doi.org/10.1007/s11136-018-2021-2).
Check out all our publications on Research Gate.
UMC-Mainz researchers have published an overview of the PanCareLIFE project in the German journal Onkologe, Europäische PanCare-Studien zu Spätfolgen nach Krebs im Kindes- und Jugendalter, Onkologe 2018 24:754–759.
You can read the full article here!
Our latest paper, published in the European Journal of Cancer, describes the scientific rationale for the PanCareLIFE project (103:227 – 237 (2018)).
Read more here!
The WP3 team has published their protocol paper on two fertility studies completed as part of PanCareLIFE:
Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE) in JMIR Res Protoc. (2018 14;7(9):e10824).
You can read the full open access paper here!
It’s hard to believe it’s been over 10 years since the first Erice statement in 2016, which laid out 10 key points summarising the essential components of cure and care for childhood cancer survivors!
In Nov 2016, 65 pediatric cancer experts from 17 European countries and North America, including many members of the PanCareLIFE team, met in Erice as part of the semi-annual PanCare meeting to review the original statement. They have now published an updated version of the statement in the Journal of Cancer Survivorship (https://doi.org/10.1007/s11764-018-0701-0).
Check out our latest open access publication in Critical Reviews in Oncology/Hematology!
The March edition of the FNM newsletter includes a feature on PanCareLIFE. The article describes how the paradigm in childhood oncology has changed from acute care to cure cancer to chronic care, where there is a focus on cure but also on prevention of late effects and their lifelong, informed management. Lifelong management relies on systematic research in late effects, like that conducted in PanCareLIFE, as well as sophisticated systems of care transition for adult survivors and empowering survivors to co-manage their own care through initiatives like Together to Smile in the Czech Republic.
You can read more in Czech here.
Check out the latest open access publication from our sister project PanCareSurFup in the European Journal of Epidemiology!
PanCareLIFE researchers at UNIBE have just published a new paper ‘Audiological monitoring in Swiss childhood cancer patients’, funded in part by PanCareLIFE.
Pediatric Blood & Cancer, 65(3) e26877, DOI: 10.1080/08880018.2017.1323985
Full audiological monitoring is the best strategy to detect hearing loss early and to provide timely intervention in the absence of a clinical method of otoprotection. Full monitoring requires audiological evaluation before, and then during and after ototoxic cancer treatment. In a worldwide context of monitoring protocols that vary substantially, we analyzed the audiological monitoring of childhood cancer patients over the last decade across treatment centers in Switzerland.
We retrospectively searched for audiological evaluations in all nine Swiss Pediatric Oncology Centers. We analyzed proportions of patients who had audiological monitoring and described type and timing of monitoring. We determined predictors of audiological monitoring using multivariable logistic regression and described time trends.
We included 185 patients from the Swiss Childhood Cancer Registry diagnosed from 2005 to 2013 who had platinum chemotherapy and/or cranial radiation ≥30 Gray and who were alive at time of study. Less than half of children, 43%, had full audiological monitoring (before, during, and after treatment), while 72% were tested after cancer treatment. Nonstudy patients were less likely to have had monitoring in all phases of cancer treatment. Patients who received treatment with cisplatin or both platinum chemotherapy and cranial radiation were more likely to have had monitoring after treatment. Monitoring during and after treatment increased over the study period, but monitoring before treatment was insufficient in all time periods.
Our population-based study indicates that audiological monitoring is insufficient in Switzerland, particularly for nonstudy patients. Clinicians must become more aware of the importance of full audiological monitoring.
PanCareLIFE partners at UNIBE have published the results of their work on ‘Audiological monitoring in Swiss childhood cancer patients’ in Pediatric Blood & Cancer (A. Weiss et al. 2017;e26877, https://doi.org/10.1002/pbc.26877).
Abstract Background: Full audiological monitoring is the best strategy to detect hearing loss early and to provide timely intervention in the absence of a clinical method of otoprotection. Full monitoring requires audiological evaluation before, and then during and after ototoxic cancer treatment. In a worldwide context of monitoring protocols that vary substantially, we analyzed the audiological monitoring of childhood cancer patients over the last decade across treatment centers in Switzerland.
Procedure: We retrospectively searched for audiological evaluations in all nine Swiss Pediatric Oncology Centers. We analyzed proportions of patients who had audiological monitoring and described type and timing of monitoring. We determined predictors of audiological monitoring using multivariable logistic regression and described time trends.
Results: We included 185 patients from the Swiss Childhood Cancer Registry diagnosed from 2005 to 2013 who had platinum chemotherapy and/or cranial radiation ≥30 Gray and who were alive at time of study. Less than half of children, 43%, had full audiological monitoring (before, during, and after treatment), while 72% were tested after cancer treatment. Nonstudy patients were less likely to have had monitoring in all phases of cancer treatment. Patients who received treatment with cisplatin or both platinum chemotherapy and cranial radiation were more likely to have had monitoring after treatment. Monitoring during and after treatment increased over the study period, but monitoring before treatment was insufficient in all time periods.
Conclusions: Our population-based study indicates that audiological monitoring is insufficient in Switzerland, particularly for nonstudy patients. Clinicians must become more aware of the importance of full audiological monitoring.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602030. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
